New drug combo under watch for Kids' lymphoma
NCT ID NCT05481437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks side effects of the drug ADCETRIS (brentuximab vedotin) when given with standard chemotherapy to children and teenagers with untreated CD30-positive Hodgkin lymphoma. The main focus is on serious side effects like low blood counts, nerve damage, and lung problems. The study will follow 8 participants in Japan for 26 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Could bone marrow from deceased donors cure blood cancers?
- Could an ALS drug clear the fog of chemo brain?